drug
tecovirimat
Marketedupdated 3mo agoby $NNVC NANOVIRICIDES, INC.
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying tecovirimat
- phase2Study to Assess the Safety and Immunogenicity of TPOXX® When Administered Orally for 28 Days With JYNNEOS
- phase3Study of Tecovirimat for Human Mpox Virus
- —Tecovirimat Intravenous Treatment for Orthopox Virus Exposure
- phase4Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binders
- phase3Safety, Tolerability and Pharmacokinetics of TPOXX When Administered Orally for 28 Days
- phase4Safety, Tolerability and PK of TPOXX in Adults Weighing More Than 120 KG
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jul 23, 2027
336 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (10)
- Aug 8, 2032method-of-use (U-2346)US 11890270
- Sep 4, 2031method-of-use (U-2346)US 7737168
- Sep 4, 2031method-of-use (U-3377)US 7737168
- Aug 2, 2031formulationUS 105761655.0y
- Aug 2, 2031formulationUS 92330975.0y
- Aug 2, 2031method-of-use (U-3377)US 99078595.0y
- Mar 23, 2031formulationUS 124338684.6y
- Mar 23, 2031compositionUS 93394664.6y
- Jul 23, 2027formulationUS 8039504336d
- Jul 23, 2027formulationUS 8039504336d
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 39m ago
Found something off?
comments(0)
5-min edit window · permanent after that